Intellia Therapeutics (NTLA) Tax Provisions (2015)

Intellia Therapeutics (NTLA) posted quarterly Tax Provisions of -$246000.0 for Q4 2015, up 12.77% quarter-over-quarter from -$282000.0 in Q3 2015.

Intellia Therapeutics (NTLA) Tax Provisions (2015) Analysis & Trends

Intellia Therapeutics (NTLA) has reported Tax Provisions for 1 consecutive years, with -$246000.0 the latest figure, recorded in Q4 2015.

In Q4 2015, Tax Provisions changed N/A year-over-year to -$246000.0; the TTM figure through Sep 2016 stood at -$246000.0 (changed N/A YoY), while the FY2015 annual figure was -$1.0 million, changed N/A from the prior year.
Tax Provisions improved to -$246000.0 in Q4 2015 per NTLA's latest filing, from -$282000.0 in the prior quarter.
Across five years, Tax Provisions topped out at -$102000.0 in Q1 2015 and bottomed at -$382000.0 in Q2 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	59.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	75.45 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	267.73
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.31 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	1.90 Mn
10	Intellia Therapeutics	1.67 Bn	1.67 Bn	-	-

Download Data